CredenceResearch.com has Published New Research Report Title “Fumaric Acid Market-Growth, Share, Opportunities & Competitive Analysis, 2015 -2022”

According to a new market report published by Credence Research “Fumaric Acid Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast 2015 – 2021,” the fumaric acid market was valued at US$ 3.70 Bn in 2015, and is expected to reach US$ 5.69 Bn by 2022, expanding at a CAGR of 6.3% from 2016 to 2022.

Browse the full Fumaric Acid Market for Food & Beverages, Unsaturated Polyester Resins (UPR), Alkyd Resins, Printing Inks, Paper Sizing and Other Applications- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2015 – 2021 report at:
http://www.credenceresearch.com/report/fumaric-acid-market

Market Insights

Fumaric acid which is also known as trans-butenedioic acid is witnessed to experience high demand from various applications in the global market. The benefits such as increasing the shelf life of food and flavor enhancement among others are the major factor for high demand from the food and beverages industry. The growing demand for unsaturated polyesters resins from the automobile industry is another factor promoting the growth of global fumaric acid market.

Growing health awareness among the population has led to adoption of nutritional diets. This has increased the demand for processed foods and drinks. Therefore, high demand for fumaric acid is observed, as it is used as preservative for processed foods and drinks. Rise in use of automobiles in emerging economies is expected to increase automobile industry in Thailand and Indonesia. Rising economic conditions in the countries such as China and India has led to high demand for unsaturated polyester resins thereby leading to growth of fumaric acid in the market. The benefits such as flavor stability, persistent sour taste, and greater buffering capacity among other benefits are expected to offer high opportunities for industrial applications in the market.

Competitive Insights:

Food & Beverages was leading the application segment with more than 25% share of global fumaric acid market. The beneficial properties of fumaric acid such as flavor enhancer, preservative and pH controller are expected to boost market demand from the food 7 beverages industry. Fumaric acid is used in the production of bakery, breads, confectionary, desserts, etc. Hence, high demand for fumaric acid is reported from the food industry. Unsaturated polyester resins accounted to be the second largest application segment in 2015 and is expected to retain its market position during the forecast period. High demand for unsaturated polyester resins from the automobile and marine industries has led to increased production and demand for fumaric acid. Other application such as alkyd resins, printing inks, paper sizing, animal feed and cleansing agents are also projected to offer high opportunities for growth of fumaric acid market during the forecast period from 2016 to 2022.

Major players involved in the production and sales of fumaric acid are focusing on synthesis of fumaric acid through fermentation processes globally. To increase market opportunities, the major weapon used by small as well as major players is backward and forward integration. In-house synthesis of fumaric acid will help reduce cost of raw material and will add to the product portfolio of the company. Hence, strong competition is observed between the prominent and major players in the market.

For More Information, List of Figure, Tables And TOC Visit:
http://www.credenceresearch.com/report/fumaric-acid-market

Key Trends:

• Manufacture of various food products
• Potential substitute to tartaric acid and citric acid
• Developments in the automobile sector
• Opportunities for growth in construction and paints & coatings market

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa. 

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

What we do

We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.

No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.

Web:  Credence Research

Blog: http://www.pdfdevices.com/fumaric-acid-market-is-expected-to-reach-us-5-69-bn-by-2022-credence-research/

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1459155921.png

Media Contact
Company Name: Credence Research
Contact Person: Chris Smith, Global Sales Manager
Email: sales@credenceresearch.com
Phone: 1-800-361-8290
Address:105 N 1st ST #429
City: SAN JOSE
State: California
Country: United States
Website: http://www.credenceresearch.com/report/fumaric-acid-market

Source: ABNewswire

ReleaseID: 57572

The Airwheel Z5 foldable electric scooter is an innovative electric means of transport that combines the minimal size of a scooter with the ability to move about independently, thanks to a small but powerful silent motor, creating a hybrid that is both fun and practical. When enjoyment meets practicality, Airwheel Z5 standing up electric scooter was born.

Airwheel Z5 electric standing scooter has joined Z series, which is ideal for getting around in the city and for anyone who needs to have a vehicle at hand at any time. The Airwheel Z5 foldable electric scooter is an innovative electric means of transport that combines the minimal size of a scooter with the ability to move about independently, thanks to a small but powerful silent motor, creating a hybrid that is both fun and practical. When enjoyment meets practicality, Airwheel Z5 standing up electric scooter was born.

Image: http://www.airwheel.net/images/airwheel_z5_scooter.jpg

The Airwheel Z5 is not only easy to use and practical to ride in any urban situation advocating portability and convenience. Its intelligent design is fully manifested when it comes to storing: triple folding system of Z5 fast electric scooter enables individuals to easily carry it into elevator, subway, bus, or store it in the trunk of a car. With light weight, even girls can life it without effort. It will be a good assistant to facilitate the daily commuting, as it allows riders to travel freely, regardless of the road traffic.

The replaceable battery on Airwheel Z3 foldable electric scooter has been upgraded into a modular battery design on Airwheel Z5 2-wheeled electric scooter, which is easier to disassemble and replace. While the main difference lies in the USB power supply interface on the front of the battery. In other words, the battery can not only provide electricity for Airwheel Z5, but also for mobile phones and other daily intelligent equipment.

Image: http://www.airwheel.net/scooters/new-product.jpg

You may feel rest assured that the safety of Airwheel Z5 is ensured. There are specifically designed headlight and intelligent brake taillight mounted on Airwheel Z5 standing up electric scooter ensures a safe riding at night and will give others warning as well. When enjoyment meets practicality, Airwheel Z5 standing up electric scooter was born.

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1459223457.jpeg

“When enjoyment meets practicality, Airwheel Z5 razor electric scooter for adults was born.”

Media Contact
Company Name: Airwheel Technology Holding (USA) Co., Ltd
Contact Person: Eric
Email: sales@airwheel.net
Phone: +8618651968700
Country: United States
Website: http://www.airwheel.net

Source: ABNewswire

ReleaseID: 57560

March 29, 2016 – – TheProductLawyers.com reports on concerning reports that type-2 diabetes drug Invokana has been linked to the development of severe kidney damage and kidney failure through adverse event reports to the U.S. Food and Drug Administration. The agency described having received 50 adverse event reports concerning renal impairment and kidney failure among patients taking the drug within its first year on the market alone.

Invokana is a new-generation diabetes drug which was approved by the FDA in March of 2013. It works by managing blood sugar (glucose) levels in type-2 diabetes patients. It does this by blocking the kidneys from reabsorbing extra sugar and instead using them to remove that sugar from the body through urination. The drug was the first to be released out of a group of similar new-generation drugs known as an SGLT2 class inhibitors. This is an abbreviation for sodium-glucose cotransporter-2.

Due to the fact that Invokana relies heavily upon the kidneys to do its job, it is now being alleged that it can potentially damage the organs or cause them stress. Many believe that these risks can be exacerbated among patients who have preexisting kidney damage, as is common for many diabetics due to the fact that diabetes is a condition which is notably hard on the kidneys.

The U.S. Food and Drug Administration announced a public safety communication on December 4, 2015, which discussed new label warning requirements for Invokana which would better address certain potential side effect risks. The agency noted that they had been in receipt of 19 reports detailing adverse events among patients who had claimed they developed life-threatening complications which started as urinary tract infections (UTIs) but later spread to blood or kidney infections. Because Invokana helps the kidneys to dispose of excess sugar through urine, the presence of extra sugar in this area can also cause the presence of extra bacteria. Each of the 19 patients detailed within these reports claim to have required hospitalization and dialysis, a kidney failure treatment. When kidney damage is sustained, it cannot be reversed, and therefore, patients with substantially damaged kidneys generally require dialysis until they are able to find a kidney transplant.

Kidney damage has also been the subject of a recent Invokana lawsuit, in addition to another potentially life-threatening side effect called diabetic ketoacidosis. Lawsuits discussing Invokana side effect allegations are filed against Invokana manufacturer and Johnson & Johnson subsidiary Janssen Pharmaceuticals.

The attorneys of Banville Law understand how concerning these potential side effect links are for patients currently using Invokana. They are dedicated to maintaining public awareness of any important safety information on Invokana or other similar SGLT2 class inhibitor drugs. To better accomplish this, they sponsor the online resource website TheProductLawyers.com. Additionally, the attorneys of Banville Law are now working to help patients who have taken these types of drugs and suffered from adverse events that they believe were caused by their use of the drugs. Banville Law attorneys want to ensure that these patients are given the important opportunity to investigate their legal rights in the matter. To help those wishing to investigate their legal options fully, the attorneys of Banville Law are offering complimentary legal consultations to affected individuals at this time, who may be eligible for significant compensation.

To ask questions regarding Invokana lawsuits, or to request additional information, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008954

Michael Wen life hacker and inventor from Toronto, Ontario, Canada recently launched a crowdfunding campaign for his latest product TapUSB touch on/off USB power switch. He has developed TapUSB to be an interchangeable touch switch as a better and much easier alternative of pulling out the cable or the conventional flip switches.

There has been a surge of USB powered devices, especially USB LED devices, in the recent years, the market is full of different devices, gadgets, tools and toys that all use the USB ports for power. However, most of these do not come with a built in switch, which makes their use somewhat inconvenient. GTA Wireless wanted to resolve this problem by developing an interchangeable, easy to use and reliable switch that can be used  by plugging TapUSB between the USB power port and the USB device.

Mike said: “It all began when I fell in love with USB powered LED bulbs/lights/lamps in early 2015, I saw how cheap LED lights had become when I was browsing Amazon and eBay, some are selling for less than $1. So I bought a bunch of different USB bulbs, lamps and night lights. However, Most of USB LED bulbs/lights/lamps do not have a built-in switch, it is not convenient to plug in and pull out all the time. Finally,  I decided to design one myself.”

The “TapUSB Tap on/off USB power” switch project is currently in need of funding, therefore, GTAWireless has taken the initiative to launch a crowdfunding campaign on one of the most popular crowdfunding platforms Kickstarter.

The funds raised through the current crowdfunding campaign will be allocated to various aspects necessary for the completion of the product for customer use. A majority of the funding will be assigned to developing an easy to use, reliable and functional device, funds will also be used to market TapUSB to a large target market. A variety of different rewards and perks are also being offered to prize the generosity of those who support the campaign and the project through their monetary contributions.

To learn more and support the campaign, please visit: https://www.kickstarter.com/projects/786298545/tapusb-one-tap-to-switch-on-off-the-power-from-a-u

About us:

Micheal Wen loves to hack software and hardware to create innovative and useful solutions that make life easier. He also loves photography as a hobby.

For more information, please visit: http://www.tapusb.com/

Media Contact
Company Name: GTA Wireless
Contact Person: Mike Wen
Email: mikewen@gta-wireless.com
City: Toronto
State: Ontario
Country: Canada
Website: http://www.tapusb.com/

Source: ABNewswire

ReleaseID: 57557

March 29, 2016 – – ZofranLegal.com reports on new controversies surrounding Zofran lawsuits in Boston, Massachusetts, as parents from across the United States continue to file complaints against the anti-nausea drug manufacturer GlaxoSmithKline, claiming that exposure to the drug while developing in the womb caused unborn babies to develop a range of severe and sometimes fatal birth defects.

In March of 2016, parents filed a lawsuit against GSK in the U.S. District Court for the Western District Court of Louisiana, Lafayette Division, claiming that fetal exposure to Zofran caused their son to develop congenital heart defects while in utero. The boy’s mother was prescribed Zofran during her first trimester of pregnancy to treat morning sickness. While the first trimester is a common time to experience nausea and vomiting associated with morning sickness, it is also a time when the fetus does much of its initial heart, limb, and mouth tissue formation. The son was reportedly born in November of 2012 and at this time he was diagnosed with the heart defects, and his parents were informed that he required immediate heart surgery, as well as extensive follow-up treatment.

Unfortunately, these parents are not alone in their claims. From across the United States, more than 220 parents have stepped forward to date, alleging that their children, who were also exposed to Zofran while in utero, have developed birth defects, including: cleft lip and palate, atrial septal and ventricular septal defects, transposition of the greater vessels, kidney defects, club foot, and respiratory distress syndrome.

Plaintiffs involved in these lawsuits commonly note that the drug was marketed and prescribed “off-label.” This term means that the drug was never FDA-approved to treat pregnant women for morning sickness. Zofran was instead approved by the FDA to treat nausea and vomiting episodes among patients who have recently undergone radiation, chemotherapy, or anesthesia. Reportedly, however, pharmaceutical giant GSK went on to market the drug as a safe and effective treatment for expectant mothers going through morning sickness to OB/GYNs as well as the general public. This led to “off-label” prescriptions, which were reportedly given to over 1 million women during just one year’s time.

As these plaintiffs await trials, the attorneys of Monheit Law are working to assist any women who used Zofran while pregnant and who subsequently gave birth to children with defects. They want to ensure that these women are provided with the important opportunity to evaluate their legal rights in full. Affected mothers, families, and children may be entitled to significant compensation attained through legal action. To better assist those who wish to look further into their legal rights, the attorneys of Monheit Law are also currently offering free legal consultations for qualifying parties.

To request additional information on Zofran lawsuits, or to ask questions, please contact Attorney Michael Monheit, Lead Attorney of Monheit Law, by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60008953

March 29, 2016 – – BloodThinnerHelp.com reports on an article recently published in the Calgary Sun discussing the a class action lawsuit which was filed against Bayer Inc., one manufacturer of the new-generation, blood-thinning drug Xarelto in Calgary, Canada. According to the head plaintiff in this Canadian class action lawsuit, the drug caused her to suffer from an uncontrollable bleeding episode which allegedly almost led to cardiac arrest.

This Canadian class action lawsuit closely follows the formation of Multidistrict Litigation number 2592 in the United States, which involves a group of more than 2,800 lawsuits filed against Xarelto. This MDL was formed by the U.S. Judicial Panel on Multidistrict Litigation. In addition to this group of Xarelto lawsuits in the United States, another group of more than 600 cases has formed a mass tort program in Philadelphia, Pennsylvania, created by the Court of Common Pleas. These lawsuits were filed against Bayer as well as Johnson & Johnson subsidiary, Janssen Pharmaceuticals.

According to the Calgary Sun, it was reported that as of March 2015, Health Canada had received around 1,100 reports detailing adverse events experienced by patients using Xarelto. The article notes that, according to a Toronto lawyer, if the class action is successful, “…it would be in the millions of dollars.” The article notes that another class action suit may be forming in Ontario as well.

In the United States, Xarelto gained FDA approval in 2011 to treat patients with pulmonary embolism, deep vein thrombosis, and atrial fibrillation, as well as those recovering from hip and knee replacement surgeries. The drug was initially popular, launching onto the market as a revolutionary blood thinner that provided patients with more freedoms than traditional blood thinners had in the past. Since this time, however, Xarelto has become the subject of increasing controversies and is regarded by many as one of the most dangerous blood thinners on the market. The FDA has given the product two “black box” warnings, which are the most severe warnings a product can receive before being completely pulled from the market.

Commonly reported side effects that have been attributed to the drug by those filing suits are pulmonary embolisms (blood clots in the lung), rectal bleeding, heart attack, stroke, epidural hematoma, internal bleeding, gastrointestinal bleeding and brain hemorrhages.

As thousands of Xarelto lawsuit plaintiffs await trial, those involved expect that lawsuit numbers surrounding the anticoagulant drug will only continue to rise. As this continues, Attorney Joseph Osborne is working to help ensure that patients who believe they have suffered from adverse health events due to their use of Xarelto will be given the opportunity to fully evaluate their legal rights in the matter. These patients may be entitled to significant compensation attained through legal action. To better assist those affected, Attorney Osborne is offering complimentary legal consultations for qualified parties at this time.

To request additional information concerning Xarelto lawsuits, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008955